1-7 of 7
Virginia Olivia Volpe
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Clone Size By Conventional Cytogenetics in Myelodysplastic Syndromes Correlates with Clinical Features and Outcomes

Rami S. Komrokji, Najla Al Ali, Virginia Olivia Volpe, Onyee Chan, Andrew Kuykendall, Kendra Sweet, Jeffrey E. Lancet, Eric Padron, David A. Sallman
Journal: Blood
Blood (2022) 140 (Supplement 1): 9804–9805.
https://doi.org/10.1182/blood-2022-168439
Published: 2022
Journal Articles

Outcomes By Best Response with Hypomethylating Agent Plus Venetoclax in Adults with Previously Untreated Acute Myeloid Leukemia

Virginia Olivia Volpe, Akriti G Jain, Onyee Chan, Eric Padron, David A. Sallman, Rami S. Komrokji, Jeffrey E. Lancet, Kendra Sweet
Journal: Blood
Blood (2021) 138 (Supplement 1): 2292.
https://doi.org/10.1182/blood-2021-149782
Published: 2021
Journal Articles

Comparative Outcomes and Molecular Response Predictors of IDH1/2-Mutated Adult Acute Myeloid Leukemia (AML) Patients (Pts) after Frontline Treatment with Intensive Induction Chemotherapy (IC), Targeted Inhibitors, or Hypomethylating Agents (HMA) (Alliance)

Uma Borate, Prapti A. Patel, Chetasi Talati, Jessica Kohlschmidt, Michael P. Ozga, Yazan F. Madanat, Luke Fletcher, Ravi Patel, Krzysztof Mrózek, Deedra Nicolet, Akriti G Jain, Virginia Olivia Volpe, Fei Yang, Richard D. Press, Daniel Jones, James S. Blachly, Christopher J. Walker, Andrew J Carroll, Guido Marcucci, Maria R. Baer, William Blum, Bayard L. Powell, Jonathan E Kolitz, Richard A. Larson, Richard M. Stone, John C. Byrd, Alice S. Mims, Kendra Sweet, Ann-Kathrin Eisfeld
Journal: Blood
Blood (2021) 138 (Supplement 1): 226.
https://doi.org/10.1182/blood-2021-152838
Published: 2021
Journal Articles

High MYC Expression Predicts Poor Survival Outcomes in IDH1/2 Mutant AML Patients

Virginia Olivia Volpe, Nicole D. Vincelette, Onyee Chan, Chetasi Talati, Kendra Sweet, Andrew T. Kuykendall, Constantine Logothetis, Rami S. Komrokji, Gregoire Calon, Nathan P. Horvat, David A. Sallman, Eric Padron, Ling Zhang, Seongseok Yun
Journal: Blood
Blood (2021) 138 (Supplement 1): 2377.
https://doi.org/10.1182/blood-2021-147030
Published: 2021
Journal Articles

SF3B1 Splicing Mutation in the Context of Therapy Related MDS

Virginia Olivia Volpe, MD, Najla Al Ali, M.Sc, Onyee Chan, MD, Eric Padron, MD, David A. Sallman, MD, Rami S. Komrokji, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 31–32.
https://doi.org/10.1182/blood-2020-138833
Published: 2020
Journal Articles

A Phase II Trial of Ibrutinib and PD-1 Blockade in Asymptomatic High Risk Chronic Lymphocytic Leukemia to Improve Immune Function

Julio C. Chavez, MD, Ariel F Grajales-Cruz, MD, Virginia Olivia Volpe, MD, Elyce P. Turba, MSN, RN, Lisa Nodzon, PhD ARNP, AOCNP, Eva Sahakian, PhD, Nicole Rozario, Javier Pinilla Ibarz, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5483.
https://doi.org/10.1182/blood-2019-132211
Published: 2019
Journal Articles

Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Retrospective, Single-Institution Analysis Based on Risk Features and Debulking Strategy with Anti-CD20 Monoclonal Antibody

Ariel F Grajales-Cruz, MD, Julio Chavez, Virginia Olivia Volpe, MD, Jose Sandoval-Sus, MD, Bijal Shah, MD, Celeste Bello, MD, Lubomir Sokol, MD PhD, Shanel Fisher, Rajesh R Nair, PhD, Yun Seongseok, MD, Hayder Saeed, MD, Leidy Isenalumhe, MD, Elyce P. Turba, MSN, RN, Lisa Nodzon, PhD ARNP, AOCNP, Javier Pinilla Ibarz, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5484.
https://doi.org/10.1182/blood-2019-129260
Published: 2019